ClinicalTrials.gov
public full text
Public Domain
The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders
This is a single-center, randomized, open-label, placebo-controlled, dose-escalation trial. The objective of this research is to evaluate the safety, tolerability, and efficacy of intrathecal administration of human-induced neural stem cell-derived extracellular vesicles (NouvSoma001) for the treatment of neuromyelitis optica spectrum disorders.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- First-in-man Study of Single Ascending Dose of a New Drug for Neurological Disorders#904342
- A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.#1164459
- Longitudinal Spinal Cord Atrophy in Patients With Neuromyelitis Optica Spectrum Disorder and Its Association With Rituximab Treatment.#265479
- To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC#913346
- Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis#859774
Record · ID 878310
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive